Holen Sie sich die Stockscreener-App
12.48
0.79%
-0.10
Handel nachbörslich:
12.70
0.22
+1.76%
Schlusskurs vom Vortag:
$12.58
Offen:
$12.62
24-Stunden-Volumen:
294.95K
Relative Volume:
0.82
Marktkapitalisierung:
$463.59M
Einnahmen:
$11.88M
Nettoeinkommen (Verlust:
$-162.08M
KGV:
-0.9997
EPS:
-12.484
Netto-Cashflow:
$-156.43M
1W Leistung:
-11.61%
1M Leistung:
-33.62%
6M Leistung:
-37.44%
1J Leistung:
+10.54%
1-Tages-Spanne:
$12.31
$13.19
1-Wochen-Bereich:
$12.18
$15.28
52-Wochen-Spanne:
$8.72
$27.41
Crescent Biopharma Inc Stock (CBIO) Company Profile
Firmenname
Crescent Biopharma Inc
Sektor
Branche
Telefon
617-430-5595
Adresse
300 FIFTH AVENUE, WALTHAM, CA
Compare CBIO vs VRTX, MRNA, REGN, ARGX, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CBIO
Crescent Biopharma Inc
|
12.48 | 463.59M | 11.88M | -162.08M | -156.43M | -12.48 |
VRTX
Vertex Pharmaceuticals Inc
|
508.75 | 128.95B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
236.50 | 94.42B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
796.34 | 81.99B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
846.27 | 53.22B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
374.08 | 42.32B | 5.76B | 514.49M | 1.10B | 4.4813 |
Crescent Biopharma Inc Stock (CBIO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-10-06 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2026-06-01 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2026-01-28 | Eingeleitet | Piper Sandler | Overweight |
| 2026-01-21 | Eingeleitet | Guggenheim | Buy |
| 2025-08-25 | Eingeleitet | Jefferies | Buy |
| 2025-08-11 | Eingeleitet | H.C. Wainwright | Buy |
| 2025-07-14 | Eingeleitet | Wedbush | Outperform |
| 2025-06-25 | Eingeleitet | Stifel | Buy |
| 2025-03-21 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2025-03-11 | Eingeleitet | Noble Capital Markets | Outperform |
| 2024-07-26 | Herabstufung | TD Cowen | Buy → Hold |
| 2023-12-22 | Eingeleitet | CapitalOne | Overweight |
| 2021-11-12 | Hochstufung | Jefferies | Hold → Buy |
| 2021-04-29 | Fortgesetzt | Stephens | Overweight |
| 2021-02-10 | Eingeleitet | Piper Sandler | Overweight |
| 2020-05-21 | Eingeleitet | Raymond James | Outperform |
| 2019-11-14 | Eingeleitet | ROTH Capital | Buy |
| 2019-08-05 | Herabstufung | Jefferies | Buy → Hold |
| 2019-08-05 | Herabstufung | Piper Jaffray | Overweight → Neutral |
| 2019-08-05 | Herabstufung | SunTrust | Buy → Hold |
| 2019-04-12 | Eingeleitet | Piper Jaffray | Overweight |
| 2019-01-04 | Eingeleitet | Oppenheimer | Outperform |
| 2018-12-18 | Eingeleitet | H.C. Wainwright | Buy |
| 2018-02-12 | Bestätigt | B. Riley FBR, Inc. | Buy |
| 2018-02-09 | Bestätigt | Chardan Capital Markets | Buy |
| 2017-12-08 | Eingeleitet | B. Riley FBR, Inc. | Buy |
| 2017-06-12 | Eingeleitet | Chardan Capital Markets | Buy |
| 2017-06-06 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2016-07-26 | Eingeleitet | SunTrust | Buy |
| 2016-06-30 | Eingeleitet | Rodman & Renshaw | Buy |
| 2015-03-17 | Bestätigt | Stifel | Buy |
Alle ansehen
Crescent Biopharma Inc Aktie (CBIO) Neueste Nachrichten
Crescent Biopharma Announces FDA Clearance of IND for CR-002 and Plans Global Phase 1/2 APOLLO Trial in Advanced Solid Tumors - Quiver Quantitative
Crescent Biopharma Announces Grants of Inducement Awards - Yahoo Finance
Crescent Biopharma (Nasdaq:CBIO)Stock Analysis - Simply Wall Street
BetterLife Pharma Raises $100 Million in a Public Offering of Shares and Warrants - Yahoo Finance
Planned 804-share sale at Crescent Biopharma (Nasdaq: CBIO) - Stock Titan
Certain Warrants of Crescent Biopharma, Inc. are subject to a Lock-Up Agreement Ending on 13-SEP-2026. - marketscreener.com
Certain Options of Crescent Biopharma, Inc. are subject to a Lock-Up Agreement Ending on 13-SEP-2026. - marketscreener.com
CBIO: Major clinical milestones and global expansion set for 2027, with key data and partnerships advancing - TradingView
Crescent Biopharma at Cantor conference: global trial push By Investing.com - Investing.com Canada
Crescent Biopharma at Cantor conference: global trial push - Investing.com India
Crescent Biopharma at Cantor conference: global trial push - investing.com
Two employees receive options tied to 58,650 Crescent Biopharma shares - Stock Titan
Crescent Biopharma Announces Grants of Inducement Awards - Yahoo Finance
Crescent Biopharma (CBIO) Surges 8.9% to $20.20 as Biotech Momentum BuildsIV Contraction - vinanet.vn
Crescent Biopharma (CBIO) Surges 8.9% to $20.20 as Biotech Momentum BuildsTRIN Signal - siam.in
Crescent Biopharma (CBIO) Surges 8.9% to $20.20 as Biotech Momentum BuildsStatistical Arbitrage - dars.gov.et
Crescent Biopharma Announces September 2026 Investor Conference Presentations - quiverquant.com
Crescent Biopharma to Present at September Investor Conferences - GlobeNewswire
Crescent Biopharma to Present at September Investor Conferences - Yahoo Finance
Crescent Capital (CCAP) holder sells at about $10.50 under trading plan - Stock Titan
Crescent Biopharma, Inc. (NASDAQ:CBIO) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Balyasny Asset Management L.P. Expands Stake in Crescent Biophar - GuruFocus
Crescent Biopharma (NASDAQ:CBIO) Stock Price Up 4.9%Should You Buy? - MarketBeat
Balyasny Asset Management (CBIO) discloses 6.03% Crescent Biopharma ownership - Stock Titan
Crescent Biopharma (NASDAQ:CBIO) Shares Gap DownShould You Sell? - MarketBeat
Crescent Biopharma (CBIO) Shares Dip 2.86% as Stock Approaches Key $16 Support LevelDay Trade Opportunities - vinanet.vn
CBIO Q2 2026 Earnings: Narrower-Than-Expected Loss Buoys SharesRevenue Miss Report - vinanet.vn
Crescent Biopharma Ord Shs (CBIO) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Q3 EPS Forecast for Crescent Biopharma Lowered by Analyst - marketbeat.com
Analysts Offer Insights on Healthcare Companies: Dyne Therapeutics (DYN) and Crescent Biopharma (CBIO) - The Globe and Mail
Crescent Biopharma Announces Grants of Inducement Awards - The Manila Times
Crescent Biopharma Announces Grants of Inducement Awards - GlobeNewswire
CRESCENT BIOPHARMA, INC. SEC Filing (Aug 3, 2026) - Stock Titan
Perceptive Advisors LLC Lowers Stake in Crescent Biopharma, Inc. $CBIO - MarketBeat
Crescent Biopharma (CBIO) Gets a Buy from Wedbush - The Globe and Mail
Crescent Biopharma Announces Q2 2026 Financial Results and Operational Update - Kalkine Media
Crescent Biopharma Reports Q2 2026 Results and Advances Clinical Development of CR-001, CR-002 and CR-003 - Quiver Quantitative
Crescent Biopharma: Q2 Earnings Snapshot - KING5.com
Crescent Biopharma posts $24.8 million Q2 net loss - Quiver Quantitative
Crescent Biopharma Reports Second Quarter 2026 Financial Results and Recent Business Highlights - GlobeNewswire
Crescent Biopharma posts $24.8 million Q2 net loss - quiverquant.com
CBIO Q1 2026 Earnings: EPS Beat Despite Pre-Revenue Status; Stock DeclinesEPS Guidance Update - vinanet.vn
Crescent Biopharma Ord Shs (CBIO) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Crescent Biopharma Ord Shs (CBIO) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Crescent Biopharma Market Sentiment - Benzinga España
Crescent Biopharma, Inc. (NASDAQ:CBIO) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Crescent Biopharma Ord Shs (CBIO) Institutional Confidence - TradingKey
CBIO Q1 2026 Earnings: Narrower Loss Surprises Analysts as Cash Management ImprovesEarnings Quality Score - vinanet.vn
CBIO|Crescent Biopharma Ord Shs|Price:16.300|Chg%:-0.730 - TradingKey
Crescent Biopharma (CBIO) Shares Dip 4.3% as Stock Pulls Back Toward Key SupportDefined Outcome ETF - dars.gov.et
Finanzdaten der Crescent Biopharma Inc-Aktie (CBIO)
Umsatz
Nettogewinn
Free Cashflow
ENV
Crescent Biopharma Inc-Aktie (CBIO) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Joshua T Brumm | Officer |
Sep 18 '26 |
Proposed Sale |
17.18 |
9,013 |
154,843 |
0 |
| Jonathan McNeill | Officer |
Sep 18 '26 |
Proposed Sale |
17.18 |
4,415 |
75,850 |
0 |
| McNeill Jonathan | President and COO |
Sep 18 '26 |
Sale |
16.71 |
3,839 |
64,150 |
134,588 |
| Brumm Joshua T | Chief Executive Officer |
Sep 18 '26 |
Sale |
16.71 |
7,837 |
130,956 |
271,765 |
| Brumm Joshua T | Chief Executive Officer |
Sep 16 '26 |
Sale |
17.90 |
1,610 |
28,819 |
279,602 |
| McNeill Jonathan | President and COO |
Sep 16 '26 |
Sale |
17.90 |
731 |
13,085 |
138,427 |
| Jonathan McNeill | Officer |
Sep 16 '26 |
Proposed Sale |
18.80 |
804 |
15,115 |
0 |
| Joshua T Brumm | Officer |
Sep 16 '26 |
Proposed Sale |
18.80 |
1,771 |
33,295 |
0 |
| Pinkas Jan | Chief Scientific Officer |
Sep 16 '26 |
Sale |
17.90 |
658 |
11,778 |
21,581 |
| Im Ellie Eunkyung | Chief Medical Officer |
Sep 16 '26 |
Sale |
17.90 |
623 |
11,152 |
21,446 |
1.35%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):